ANGPTL3 inactivating antibody administration reduced circulating plasma levels of TG, LDL-cholesterol, and HDL-cholesterol in dyslipidemic mice and monkeys.
Angiopoietin-like protein 3 (ANGPTL3) is a secretory protein regulating plasma lipid levels via affecting lipoprotein lipase- and endothelial lipase-mediated hydrolysis of triglycerides and phospholipids. ANGPTL3-deficiency due to loss-of-function mutations in the ANGPTL3 gene causes familial combined hypobetalipoproteinemia (FHBL2, OMIM # 605019), a phenotype characterized by low concentration of all major lipoprotein classes in circulation. ANGPTL3 is therefore a potential therapeutic target to treat combined hyperlipidemia, a major risk factor for atherosclerotic coronary heart disease. This review focuses on the mechanisms behind ANGPTL3-deficiency induced FHBL2.
Tikka et al. (Mon,) conducted a other in familial combined hypobetalipoproteinemia (FHBL2). ANGPTL3 inactivating antibody was evaluated on Reduction in plasma levels of TG, LDL-cholesterol, and HDL-cholesterol. ANGPTL3 inactivating antibody administration reduced circulating plasma levels of TG, LDL-cholesterol, and HDL-cholesterol in dyslipidemic mice and monkeys.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: